← Back to Clinical Trials
Recruiting NCT05876130
Postoperative Hypofractionated Intensity-modulated Radiotherapy Endometrial Cancer
Trial Parameters
Condition Endometrial Cancer
Sponsor Samsung Medical Center
Study Type INTERVENTIONAL
Phase N/A
Enrollment 92
Sex FEMALE
Min Age 20 Years
Max Age 80 Years
Start Date 2022-11-01
Completion 2031-12-31
Interventions
POHIM_EM
Brief Summary
To investigate the non-inferiority of disease-free survival in women who received hypofractionated intensity-modulated whole pelvic radiation therapy (2.5 Gy x 16 fractions) after curative surgery for stage III endometrial cancer.
Eligibility Criteria
Inclusion Criteria: * histologically confirmed endometrioid type endometrial cancer * completion of hysterectomy and surgical staging * pathologically confirmed FIGO stage III * ECOG performance status 0 or 1 * adjuvant chemotherapy was done or planned Exclusion Criteria: * presence of distant metastasis * previous history of pelvic radiotherapy * severe and unstable medical condition * previous history of other carcinoma except for thyroid cancer, skin cancer, and endometrial cancer
Related Trials
NCT05787587
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
View Trial →
NCT04196257
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
View Trial →
NCT06533059
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
View Trial →